Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F17%3AN0000150" target="_blank" >RIV/00064190:_____/17:N0000150 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S2213-2600(17)30219-9" target="_blank" >http://dx.doi.org/10.1016/S2213-2600(17)30219-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2213-2600(17)30219-9" target="_blank" >10.1016/S2213-2600(17)30219-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Popis výsledku v původním jazyce

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Název v anglickém jazyce

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Popis výsledku anglicky

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

LANCET RESPIRATORY MEDICINE

ISSN

2213-2600

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

591-598

Kód UT WoS článku

000404047900023

EID výsledku v databázi Scopus

—